Literature DB >> 15334065

Tumor formation in p53 mutant ovaries transplanted into wild-type female hosts.

Chun-Ming Chen1, Junn-Liang Chang, Richard R Behringer.   

Abstract

P53: gene alterations correlate highly with advanced ovarian carcinoma in women. In mice, p53 deficiency predominantly results in the formation of lymphomas and sarcomas. However, ovarian epithelial tumors have not been documented in p53 homozygous mutant (p53-/-) mice, probably because they die before other tumors can form. To determine whether p53-/- ovaries can develop epithelial tumors, they were transplanted into the ovarian bursae of histocompatible wild-type recipient females. The p53-/- ovarian grafts formed tumors approximately 1 year post-transplantation. The tumor type was angiosarcoma, suggesting that vascular tissues are predisposed to tumor formation in p53-/-ovaries. These findings suggest that p53 deficiency alone is not sufficient for ovarian epithelial tumorigenesis in mice. Thus, other genetic lesions are likely required to develop mouse models of human ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15334065     DOI: 10.1038/sj.onc.1208037

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

1.  An absence of Twist1 results in aberrant cardiac neural crest morphogenesis.

Authors:  Joshua W Vincentz; Ralston M Barnes; Rhonda Rodgers; Beth A Firulli; Simon J Conway; Anthony B Firulli
Journal:  Dev Biol       Date:  2008-05-08       Impact factor: 3.582

2.  Follicle Depletion Provides a Permissive Environment for Ovarian Carcinogenesis.

Authors:  Ying Wang; Kathy Qi Cai; Elizabeth R Smith; Toni M Yeasky; Robert Moore; Parvin Ganjei-Azar; Andres J Klein-Szanto; Andrew K Godwin; Thomas C Hamilton; Xiang-Xi Xu
Journal:  Mol Cell Biol       Date:  2016-08-26       Impact factor: 4.272

3.  Disabled-2 heterozygous mice are predisposed to endometrial and ovarian tumorigenesis and exhibit sex-biased embryonic lethality in a p53-null background.

Authors:  Dong-Hua Yang; Zia Fazili; Elizabeth R Smith; Kathy Qi Cai; Andres Klein-Szanto; Cynthia Cohen; Ira R Horowitz; Xiang-Xi Xu
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

4.  A reduction of cyclooxygenase 2 gene dosage counters the ovarian morphological aging and tumor phenotype in Wv mice.

Authors:  Wan-Lin Yang; Kathy Qi Cai; Jennifer L Smedberg; Elizabeth R Smith; Andres Klein-Szanto; Thomas C Hamilton; Xiang-Xi Xu
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

5.  Cooperative interaction of Nkx2.5 and Mef2c transcription factors during heart development.

Authors:  Joshua W Vincentz; Ralston M Barnes; Beth A Firulli; Simon J Conway; Anthony B Firulli
Journal:  Dev Dyn       Date:  2008-12       Impact factor: 3.780

Review 6.  Development of a mouse model of menopausal ovarian cancer.

Authors:  Elizabeth R Smith; Ying Wang; Xiang-Xi Xu
Journal:  Front Oncol       Date:  2014-02-26       Impact factor: 6.244

7.  Nuclear envelope structural defect underlies the main cause of aneuploidy in ovarian carcinogenesis.

Authors:  Callinice D Capo-Chichi; Toni M Yeasky; Elizabeth R Smith; Xiang-Xi Xu
Journal:  BMC Cell Biol       Date:  2016-11-22       Impact factor: 4.241

Review 8.  Defective Nuclear Lamina in Aneuploidy and Carcinogenesis.

Authors:  Elizabeth R Smith; Callinice D Capo-Chichi; Xiang-Xi Xu
Journal:  Front Oncol       Date:  2018-11-20       Impact factor: 6.244

9.  Tumor spectrum, tumor latency and tumor incidence of the Pten-deficient mice.

Authors:  Tsai-Ling Lu; Junn-Liang Chang; Chih-Chia Liang; Li-Ru You; Chun-Ming Chen
Journal:  PLoS One       Date:  2007-11-28       Impact factor: 3.240

Review 10.  Angiosarcoma of the breast, the unknown-a review of the current literature.

Authors:  Emanuela Esposito; Franca Avino; Raimondo di Giacomo; Ivana Donzelli; Ugo Marone; Maria Teresa Melucci; Chiara Rinaldo; Fulvio Ruffolo; Ruggero Saponara; Claudio Siani; Raffaele Tortoriello; Gerardo Botti; Massimo Rinaldo; Alfredo Fucito
Journal:  Transl Cancer Res       Date:  2019-10       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.